HOUSTON, TX — Moleculin Biotech, Inc. (Nasdaq: MBRX), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting hard-to-treat tumors and viruses, provided a preliminary update on recent clinical activity and expected near term milestones for its lead program MB-106 for the treatment of Acute Myeloid Leukemia...
research News
Melbourne, Australia – Australian researchers have worked out how to fix a defect that causes lupus, and hope their world-first discovery will offer effective long-term treatment. Published in Nature Communications, the Monash University-led study found a way to reprogram the defective cells of lupus patients with protective molecules from healthy...
BRONX, NY—Acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS)—two related blood diseases that disproportionally strike older adults—are notoriously difficult to treat and associated with high relapse rates. Although new therapies have improved survival, treatment options remain limited, and the prognosis for the 50% of people who experience disease relapse remains...
New York, NY – Metastatic disease, which occurs when cancer spreads from its original site to other areas of the body, is responsible for the majority of cancer-related deaths. While researchers understand how cancer cells escape the primary site to seed new tumors, it’s not well understood why some of...
London, UK – New King’s College London research reveals that interventions which improve mood can reduce levels of inflammation in people with inflammatory bowel disease by 18 per cent, compared to having no mood intervention. Researchers at the Institute of Psychiatry, Psychology & Neuroscience at King’s College London found that...
By Raffaele Pereno – PhD, MBA MILAN, Italy – At Bio Europe Spring 2025, Dr. Henrik Luessen, Chief Business Officer at Eleva Biologics, spotlighted the company’s lead therapeutic candidate, CPV-104, a recombinant human Factor H developed using Eleva’s proprietary moss-based manufacturing platform. A Unique Platform for Complex Biologics Eleva...
BOSTON – Amyotrophic lateral sclerosis (ALS) is a severe, fatal neurodegenerative disorder causing loss of motor neurons and voluntary muscle action. While mouse studies have identified potential treatments, these drugs have typically done very poorly in human trials. Researchers at Boston Children’s Hospital, working in collaboration with Pfizer, now report...
New York, NY — Scientists at the Icahn School of Medicine at Mount Sinai have identified a new class of RNAs packed into tiny particles known as extracellular vesicles (EVs) that could revolutionize how cancer and other diseases are diagnosed. The team found that these molecules undergo changes when cancer...
New York, NY – Mount Sinai researchers have identified a key driver of a blood vessel disorder known as fibromuscular dysplasia (FMD) which affects up to five percent of the adult population and can lead to high blood pressure, heart attack, or stroke. In a study published in Nature Cardiovascular...
New York, NY – In a scientific breakthrough, Mount Sinai researchers have revealed the biological mechanisms by which a family of proteins known as histone deacetylases (HDACs) activate immune system cells linked to inflammatory bowel disease (IBD) and other inflammatory diseases. This discovery, reported in Proceedings of the National Academy...